Dr. Mark Townsend, chief clinical digital ventures officer at ... "This is the first time that this type of data has really been unlocked from the traditional IT systems which are designed to ...

The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment period.

Clinical data for Revumenib and Axatilimab will be presented at EHA 2025, highlighting advancements in acute leukemia and chronic GVHD. Safety concerns regarding Revuforj are highlighted ...

Evaluation of the Clinical Utility of the Bone Metastases Ensemble Trees for Survival Decision Support Platform (BMETS-DSP): A Case-Based Pilot Assessment Data on 221 newly diagnosed patients with AML ...